Online Only Articles

Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function

Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany
Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany
Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany
Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany
Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany
Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany
Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany
Mousepathology, Animal Experimental Unit, Helmholtz-Center for Infection Research, Braunschweig, Germany
Department of Transfusion Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany
Institute of Molecular and Clinical Immunology, Otto-von-Guericke University Medical Center, Magdeburg, Germany
Institute of Molecular and Clinical Immunology, Otto-von-Guericke University Medical Center, Magdeburg, Germany;Department of Immune Control, Helmholtz Center for Infection Research, Braunschwei, Germany
Department of Experimental Pediatrics, Otto-von-Guericke University Medical Center, Magdeburg, Germany
Department of Experimental Pediatrics, Otto-von-Guericke University Medical Center, Magdeburg, Germany
Institute of Clinical Chemistry and Pathobiochemistry, Otto-von-Guericke University Medical Center, Magdeburg, Germany
Institute of Clinical Chemistry and Pathobiochemistry, Otto-von-Guericke University Medical Center, Magdeburg, Germany
Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany;German Cancer Research Center (DKFZ), Division of Epigenomics and Cancer Risk Factors, Heidelberg, Germany
Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany
Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany
Vol. 99 No. 6 (2014): June, 2014 https://doi.org/10.3324/haematol.2014.104331